An Open Label, Parallel-group Study to Determine Multiple Dose Pharmacokinetics of LCZ696 and Its Metabolites in Subjects With Mild and Moderate Renal Impairment Compared to Matched Healthy Subjects With Normal Renal Function
Latest Information Update: 09 Jun 2016
At a glance
- Drugs Sacubitril/valsartan (Primary)
- Indications Heart failure; Hypertension
- Focus Pharmacokinetics
- Sponsors Novartis Pharmaceuticals
Most Recent Events
- 26 May 2016 Results of impact of renal impairment on pharmacokinetics of LCZ-696 published in the European Journal of Clinical Pharmacology
- 13 Apr 2012 New trial record